What GLP-1 growth means for this year’s Christmas trading
As weight loss drug use grows across the UK, the shape of Christmas spending is also set to shift. Here we explore the impact of GLP-1s on baskets and how retailers can get ahead
Read the full articleYou might also wanna read
Beyond the Step Change: What GLP-1s Solved - and What They Didn’t
GLP-1 therapies have redefined what obesity pharmacotherapy can achieve, but efficacy is no longer the only battleground.
Daily weight loss pill available in UK pharmacies from today
The Wegovy tablet became the first GLP-1 pill for weight loss to be approved by the UK’s medicines regulator last month
How new weight-loss drugs may offer hope for curbing addiction
Drugmakers are racing to develop ever newer versions of the GLP-1 drugs, and regulators around the world are approving them at an equally ra
3 High Growth GLP-1 Biotech Winners to Buy in July
The GLP-1 trade has matured from a single-stock story into a tiered opportunity set. Demand for obesity therapeutics keeps expanding as lowe
Study links expanding GLP-1 use with rising overall costs
As use of GLP-1s surged across the U.S., average total payments per user also climbed sharply, according to a new Northwestern University st
The post-Ozempic economy: Investors bet on foodtech
Interest in GLP-1s is a growing global phenomenon. See why investors in adjacent lifestyle categories are taking notice.
Comments
Sign in to join the conversation.
No comments yet. Be the first.